Budget impact analysis of introducing infliximab subcutaneous for the treatment of Inflammatory Bowel Disease in Latvia

被引：0
|
作者：
Yoo, H. K. [1 ]
Jang, M. Y. [1 ]
Kwon, T. S. [2 ]
机构：
[1] Celltr Healthcare, Global Market Access, Incheon, South Korea
[2] Celltr Healthcare, Global Market, Incheon, South Korea
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P893
引用
收藏
页码：1008 / 1009
页数：2
相关论文
共 50 条
  • [1] Evaluating patient access to infliximab subcutaneous in inflammatory bowel disease
    Jang, M.
    Yoo, H.
    Kwon, T.
    [J]. JOURNAL OF CROHNS & COLITIS, 2023, 17 : 1006 - 1006
  • [2] BUDGET IMPACT ANALYSIS OF PROACTIVE THERAPEUTIC DRUG MONITORING FOR INFLAMMATORY BOWEL DISEASE PATIENTS IN THE UNITED STATES ON INFLIXIMAB THERAPY
    Dervieux, T.
    Vasquez, P.
    Shim, A.
    Simbaqueba, E.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S73 - S73
  • [3] Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease
    Smith, Philip J.
    Fumery, Mathurin
    Leong, Rupert W.
    Novak, Kerri
    Dignass, Axel
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2023, 19 (09) : 1143 - 1156
  • [4] Evaluation of the efficacy and safety of the use of subcutaneous infliximab in the treatment of inflammatory bowel disease in naive patients
    Escobar, J.
    Perez, J.
    Plaza, R.
    Castillo, M.
    Saez, O.
    Ponferrada, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1454 - I1456
  • [5] Persistence of subcutaneous infliximab after two years of the switch from intravenous infliximab to subcutaneous infliximab in Inflammatory Bowel Disease patients
    Huguet, J. M.
    Iborra, M.
    Marti, L.
    Bosca-Watts, M. M.
    Ramirez, J. J.
    Ruiz, L.
    Sanchis, L.
    Garrido, A.
    Alemany, G.
    Suria, C.
    Paredes, J. M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1242 - I1242
  • [6] Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
    Chetwood, John David
    Tran, Yvonne
    Subramanian, Sreedhar
    Smith, Philip J.
    Iborra, Marisa
    Buisson, Anthony
    Paramsothy, Sudarshan
    Leong, Rupert W.
    [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 (09): : 1440 - 1449
  • [7] COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS INFLIXIMAB FOR INFLAMMATORY BOWEL DISEASES IN SEQUENCIAL BIOLOGICAL TREATMENT
    Baik, Deborah
    Atreya, Raja
    Bouhnik, Yoram
    Casey, Daniel
    Jang, Minyoung
    Yoon, SangWook
    Kwon, Taek S.
    [J]. GASTROENTEROLOGY, 2022, 162 (07) : S678 - S679
  • [8] Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment
    Bouhnik, Yoram
    Atreya, Raja
    Casey, Daniel
    Gorecki, Michat
    Baik, Deborah
    Yoon, Sang Wook
    Kwon, Taek Sang
    Jang, Minyoung
    [J]. INFLAMMATORY BOWEL DISEASES, 2023, 29 (06) : 898 - 913
  • [9] BUDGET IMPACT ANALYSIS OF INTRODUCING SUBCUTANEOUS INFLIXIMAB CT-P13 SC FROM THE UK PAYER PERSPECTIVE
    Perry, M.
    Jang, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1879 - 1879
  • [10] Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries
    Hyun Kyeong Yoo
    Han Geul Byun
    Flavio Caprioli
    Mathurin Fumery
    Laurent Peyrin-Biroulet
    Subramanian Sreedhar
    James Potter
    Minyoung Jang
    [J]. BMC Health Services Research, 22
12345